BNT162b2
BNT162b2 is a biological therapy with 33 clinical trials. Currently 3 active trials ongoing. Historical success rate of 95.7%.
Success Metrics
Based on 22 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
10
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
95.7%
22 of 23 finished
4.3%
1 ended early
3
trials recruiting
33
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
Clinical Trials (33)
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Drug Use Investigation of COMIRNATY Intramuscular Injection
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Special Investigation of COMIRNATY in the Population With Underlying Diseases
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial
Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)
Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 33